




**Tip:** In this table display format biomarker uses are classified by **Indication Type** (Major Condition, Safety/Tox or Experimental Pathology), and by **Validity**. Use validity abbreviations in the table are: EME (Emerging); EXP (Experimental); ESH (Early Studies in Humans); LSH (Late Studies in Humans); and R/A (Recommended/Approved). Hovering with your mouse on an individual validity column header displays a tooltip with the full name.

## Working with your data:



Records Retrieved: records 1 to 10 of 160 retrieved

| Biomarker Name         | Type               | Use Indication Type and Validity          | Source          | Ref | Pat | Kit | YOMAC |
|------------------------|--------------------|---|-----------------|-----|-----|-----|-------|
| 14-3-3 protein epsilon | Proteomic; Genetic | Major Condition<br>Neurological disorders | ESH LSH R/A All | 1   | 1   | 1   |       |
| 25-Hydroxycholesterol  | Biochemical        | Major Condition<br>Neurological Disorders | ESH LSH R/A All | 2   | 2   | 2   |       |

Records Retrieved: records 1 to 25 of 160 retrieved

| Biomarker Name                          | Population Role | Technique (Substrate)         | Parameter                    | Validity (Authority)    | Source | Ref | Pat | Kit | YOMAC |
|---|-----------------|-------------------------------|------------------------------|-------------------------|--------|-----|-----|-----|-------|
| 14-3-3 protein epsilon                  | All             | Monitoring Treatment Efficacy | 2D-FASE / MALDI-TOF-MS       | Early Studies in Humans | Ref    | 1   | 0   | 1   | YOMAC |
| 25-Hydroxycholesterol                   | All             | Monitoring Treatment Efficacy | GC-MS (Plasma)               | Early Studies in Humans | Ref    | 0   | 0   | 1   | YOMAC |
| 4-aminobutanoic acid/aminobutanoic acid | All             | Monitoring Treatment Efficacy | Not specified (Not approved) | Early Studies in Humans | Ref    | 1   | 0   | 0   | 1     |

Now you can use **Filter by Statistics** tool (to the right of the table results) to refine the results. The results can be filtered based on the **biomarker** criteria, or at the **biomarker use** criteria. To see only the results for those uses that have reached a specific validity click the **Validity** chart in **Filter By Statistics** and use the checkboxes to select a subset of validity categories.

Filtering by **Validity** at the **biomarker use** level means your results subset will contain only those biomarkers with uses that have been reached the desired validity for the condition of interest, in this example, **Early Studies in Humans** and **Late Studies in Humans**.

You can now change the display of the results. Open the **Options** pulldown menu and then select **Biomarker List** from the menu.

The display changes to a list view that summarizes the information for the biomarker uses with the specific condition and role. This table displays the **Population**, **Role**, **Technique (Substrate)**, **Parameter**, **Validity**, and **Sources** associated with the **biomarker use**.

From the list of biomarkers you can refer again to **Filter by Statistics** on the right of the page to further limit the results to only those records of interest. For example, select **Population** and then from the chart select "Mild to Moderate". When you click **View Subset(s)** the results list will now contain only biomarker records that have at least one use with specified role and condition where the population is Mild to Moderate.

If you have any questions please contact us at: [DTStraining@clarivate.com](mailto:DTStraining@clarivate.com)

## Biomarker use records:

| Biomarker Use Record       |   |   |
|----------------------------|---|---|
| Biomarker                  | ApoB/cholesterol  |   |
| Link ID                    | 123456  |   |
| <b>Summary</b>             |   |   |
| Role                       | Monitoring Treatment Efficacy   |   |
| Indication Type            | Condition   |   |
| Indication                 | Dementia, Alzheimer's type  |   |
| Population                 | Mild to Moderate  |   |
| Technique                  | EAM   |   |
| Substrate                  | Cardiographic test  |   |
| Parameter                  | NA  |   |
| Validity                   | Early Studies in Humans   |   |
| Sources                    | Data - <a href="#">Study of LITINA in Mild to Moderate Alzheimer's Disease (NCT0080124)</a> |   |
| <b>Product Lines</b>       |   |   |
| Name                       | Type  | Sources   |
| LITINA-21                  | Therapeutic Agents  | Data - <a href="#">Study of LITINA in Mild to Moderate Alzheimer's Disease (NCT0080124)</a> |
| <b>Linked uses</b>         |   |   |
| <b>Related information</b> |   |   |
| <a href="#">Group All</a>  | <a href="#">External</a>  | <a href="#">Clinical</a>  |

To review in detail the use records for these biomarkers referring to the specific **Condition**, **Role**, **Validity**, and **Population of Interest**, open the **Options** pulldown menu and select **Biomarker Use Records**. The **Biomarker Use Record** provides a summary of the use as well as links to the source information along with product links which take you directly to the relevant drug records in the **Drugs & Biologics** Knowledge Area of *Integrity*.

If you have any questions please contact us at: [DTStraining@clarivate.com](mailto:DTStraining@clarivate.com)